Anti-infective skin replacement therapy - Stratatech

Drug Profile

Anti-infective skin replacement therapy - Stratatech

Alternative Names: ExpressGraft™ - Anti-microbial; ExpressGraft™ - C9T1; NIKSC9T1

Latest Information Update: 02 Feb 2017

Price : $50

At a glance

  • Originator Wisconsin Alumni Research Foundation
  • Developer Stratatech
  • Class Cell therapies
  • Mechanism of Action Cathecilidin expression stimulants; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Varicose ulcer
  • Preclinical Diabetic foot ulcer

Most Recent Events

  • 17 Jan 2017 Stratatech plans a phase-I clinical trials in Diabetic foot ulcer in USA (Topical) (NCT02657876)
  • 31 Aug 2016 Stratatech has been acquired by Mallinckrodt plc
  • 31 Aug 2016 Phase-I clinical trials in Varicose ulcer in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top